Leviathan Cannabis Hires Head of Production with Extensive North American Experience

Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Leviathan Cannabis Group Inc. (CSE: EPIC) (the "Company" or "Leviathan") announces the appointment of Dan Grady as the Company's Head of Production. Mr. Grady will oversee all aspects of Leviathan's cannabis production as the Company executes on its domestic and global plan.

Mr. Grady has over ten years of commercial scale cultivation experience in the North American cannabis industry. He has worked in Colorado, California and in Canada — where he has engineered multiple automated grow facilities from the ground up. These include indoor grows, outdoor grows, greenhouses and hybrid-green house operations - that have ranged in size from 8,000 to 450,000 square feet of cannabis production.

Mr. Grady also brings extensive knowledge in cannabis science and genetics. He has grown hundreds of different cannabis cultivars - isolating specific phenotypes for commercial production. Utilizing his vast knowledge and experience in the various industry disciplines, Mr. Grady will serve as Leviathan's lead expert responsible for growing methodologies, genetics, workflow, crop-timing, equipment requirements and personnel.

Earlier in his career, Mr. Grady served as a U.S. Marine intelligence specialist where he honed his razor-sharp focus and his ability to effectively navigate and accomplish complex goals.

"Dan Grady's multi-dimensional skillset in cannabis cultivation, genetics, hands-on operation will allow Leviathan to intelligently and efficiently develop the Company's Pelham, Ontario facility," states Martin J. Doane, Leviathan's CEO. "His talents will also the set the path for the Company to develop high-value, proprietary cannabis cultivars and products that can marketed on the global stage."

Stock Options Grant
Leviathan announces that to incentivize certain consultants to maintain a long-term relationship with the Company, and in consideration for their services and covenants under a consulting agreement, the board of directors approved the granting of stock options to two consultants exercisable for up to 600,000 Common Shares at $1.50 per share with a two-year expiration date, subject to certain vesting conditions.

About Leviathan Cannabis
Leviathan plans on executing a series of strategic acquisitions that extend across all vertical markets in Canada and internationally, to support the Company's proprietary brand strategy. This global reach positions the Company to be a leading multi-jurisdictional medical and recreational cannabis enterprise — one that brings together the best cannabis products, brands and expertise from Canada and around the world. The Leviathan portfolio currently comprises Jekyll+Hyde Brand Builders Inc., a marketing services agency specializing in the cannabis sector, and Woodstock Biomed Inc., a late-stage applicant under the ACMPR, which is in the process of retrofitting a substantial greenhouse production facility in Pelham, Ontario. Leviathan recently announced its intention to acquire Pulse Rx Inc., a boutique-style pharmacy currently providing core pharmacy services to institutional clients including nursing and retirement homes. Pulse Rx will form an integral component in Leviathan's future retail distribution model for cannabis products.

Please visit www.LeviathanCannabis.com.

For more information, contact Martin J. Doane, CEO, Leviathan Cannabis Group Inc. at 416.903.6691 or Jayne Beckwith, Chief Communications Officer at Leviathan Cannabis Group Inc. at 416.806.0591.

# # #

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or negatives of these terms and similar expressions.

Forward-looking statements are based on certain assumptions, including successful application to be a licensed cannabis producer and seller, expected growth, results from operations, performance, industry trends and growth opportunities. While Leviathan considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.

Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Leviathan to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Leviathan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Leviathan Cannabis Group Inc.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.